We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's Backing Abbott's Established Pharmaceuticals Division Growth
Read MoreHide Full Article
Key Takeaways
Abbott's EPD sales rose 8.7% comparably in Q2 2026, led by 10.7% growth in Key Emerging Markets.
Healthcare access, aging populations and treatment needs are supporting demand for established therapies.
Abbott is expanding its biosimilar pipeline to broaden EPD's portfolio and create growth opportunities.
Abbott Laboratories’ (ABT - Free Report) Established Pharmaceuticals Division (“EPD”) continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets.
In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD’s diversified geographic footprint and its ability to capitalize on growing healthcare demand across emerging markets.
The EPD business continues to benefit from favorable structural trends, including expanding access to healthcare, aging populations and increasing treatment needs for both acute and chronic conditions. These trends are expanding the addressable patient population and supporting sustained demand for established pharmaceutical therapies.
Meanwhile, Abbott is expanding its biosimilar pipeline, which should broaden EPD’s product portfolio and create additional growth opportunities across key markets. The combination of a broad product portfolio, expanding pipeline, strong brand equity and disciplined commercial execution positions EPD to sustain high-single-digit sales growth over the long term.
Peer Update
Boston Scientific’s (BSX - Free Report) international operations continue to support its growth profile, benefiting from a broad geographic presence across developed and emerging markets. In the second quarter of 2026, operational sales increased 4.2% in EMEA, 11.2% in APAC and 16.2% in Latin America and Canada.
Growth in APAC was particularly strong, with double-digit gains across Japan, China and Korea, supported by momentum in Interventional Cardiology, Electrophysiology and WATCHMAN. Looking ahead, continued expansion of the FARAPULSE ecosystem, OPAL mapping platform and WATCHMAN FLX Pro should strengthen the company’s presence and support further penetration across key international markets.
Medtronic (MDT - Free Report) also maintains a significant international presence, supported by broad-based demand for its medical technologies across multiple therapeutic areas. In fiscal 2026, international revenues totaled $18.26 billion and increased 6.2% organically, outpacing the 5.4% organic growth recorded in the United States.
International revenues maintained 6.2% organic growth in the fourth quarter, with Cardiovascular increasing 7.1%, Neuroscience growing 5.8% and Diabetes up 12.2%. Structural Heart also delivered stronger performance outside the United States, while Diabetes continued to benefit from product innovation and geographic expansion, including Simplera Sync and the EMEA launch of MiniMed Go Smart MDI with Simplera.
ABT Price Performance
In the past year, Abbott shares have plunged 14.3% compared with the industry’s 22.7% decline.
Image Source: Zacks Investment Research
ABT's Valuation
ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 3.63X compared with the industry median of 2.81X.
Image Source: Zacks Investment Research
ABT Stock Estimate Trend
In the past 30 days, ABT’s EPS estimate for 2026 has moved north 0.2%.
View the Zacks #1 Rank List
Image: Bigstock
What's Backing Abbott's Established Pharmaceuticals Division Growth
Key Takeaways
Abbott Laboratories’ (ABT - Free Report) Established Pharmaceuticals Division (“EPD”) continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets.
In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD’s diversified geographic footprint and its ability to capitalize on growing healthcare demand across emerging markets.
The EPD business continues to benefit from favorable structural trends, including expanding access to healthcare, aging populations and increasing treatment needs for both acute and chronic conditions. These trends are expanding the addressable patient population and supporting sustained demand for established pharmaceutical therapies.
Meanwhile, Abbott is expanding its biosimilar pipeline, which should broaden EPD’s product portfolio and create additional growth opportunities across key markets. The combination of a broad product portfolio, expanding pipeline, strong brand equity and disciplined commercial execution positions EPD to sustain high-single-digit sales growth over the long term.
Peer Update
Boston Scientific’s (BSX - Free Report) international operations continue to support its growth profile, benefiting from a broad geographic presence across developed and emerging markets. In the second quarter of 2026, operational sales increased 4.2% in EMEA, 11.2% in APAC and 16.2% in Latin America and Canada.
Growth in APAC was particularly strong, with double-digit gains across Japan, China and Korea, supported by momentum in Interventional Cardiology, Electrophysiology and WATCHMAN. Looking ahead, continued expansion of the FARAPULSE ecosystem, OPAL mapping platform and WATCHMAN FLX Pro should strengthen the company’s presence and support further penetration across key international markets.
Medtronic (MDT - Free Report) also maintains a significant international presence, supported by broad-based demand for its medical technologies across multiple therapeutic areas. In fiscal 2026, international revenues totaled $18.26 billion and increased 6.2% organically, outpacing the 5.4% organic growth recorded in the United States.
International revenues maintained 6.2% organic growth in the fourth quarter, with Cardiovascular increasing 7.1%, Neuroscience growing 5.8% and Diabetes up 12.2%. Structural Heart also delivered stronger performance outside the United States, while Diabetes continued to benefit from product innovation and geographic expansion, including Simplera Sync and the EMEA launch of MiniMed Go Smart MDI with Simplera.
ABT Price Performance
In the past year, Abbott shares have plunged 14.3% compared with the industry’s 22.7% decline.
Image Source: Zacks Investment Research
ABT's Valuation
ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 3.63X compared with the industry median of 2.81X.
Image Source: Zacks Investment Research
ABT Stock Estimate Trend
In the past 30 days, ABT’s EPS estimate for 2026 has moved north 0.2%.
Image Source: Zacks Investment Research
ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.